Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27463569 | 0.89 | POLB (0.64) | POLBALDH1A1MAPTKDM4EHTR1A | |
| SCHEMBL4875267 | 0.89 | ALDH1A1 (0.79) | POLBALDH1A1MAPTKDM4EHTR2A | |
| SCHEMBL19851992 | 0.87 | TSHR (0.64) | POLBALDH1A1MAPTHTR1ASMN1; SMN2 | |
| SCHEMBL8444585 | 0.84 | POLB (0.63) | POLBALDH1A1MAPTKDM4EDRD2 | |
| SCHEMBL21044195 | 0.84 | ALDH1A1 (0.72) | POLBALDH1A1MAPTHTR2AKDR | |
| SCHEMBL6301694 | 0.84 | MAPT (0.72) | POLBALDH1A1MAPTHTR1ASMN1; SMN2 | |
| SCHEMBL351997 | 0.83 | HTR1A (0.81) | ALDH1A1MAPTHTR1ADRD2HTR2A | |
| SCHEMBL8218392 | 0.83 | HTR1A (0.67) | POLBALDH1A1MAPTKDM4EHTR1A | |
| Hydrochloric Acid SCHEMBL1374296 | 0.82 | MAPT (0.70) | POLBALDH1A1MAPTKDM4EHTR1A | |
| SCHEMBL9381303 | 0.82 | ALDH1A1 (0.69) | POLBALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017157882-A1 | SERINE BIOSYNTHETIC PATHWAY INHIBITORS | Université Catholique de Louvain (BE) | 2017-09-21 | — | — | WO | disclosed |
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2012-01-19 | — | — | US | disclosed |
| US-7893261-B2 | bi-functional organic molecules which combine serotonin transporter reuptake inhibition with serotonin (5-HT, such as 5-HT2A) receptor antagonism in one molecular entity | BAYLOR UNIVERSITY (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | BAYLOR UNIVERSITY | 2008-06-05 | — | — | US | disclosed |
| EP-1732610-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005094896-A2 | TARGETED SEROTONIN REUPTAKE INHIBITORS | BAYLOR UNIVERSITY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016124-A1 | SEROTONIN REUPTAKE INHIBITORS | HTR2A, HTR2C, HTR1A | POLB 1176/4885ALDH1A1 969/4885MAPT 2011/4885 |
| US-20080132514-A1 | Serotonin Reuptake Inhibitors | HTR2A, HTR2C, HTR1A | POLB 1176/4885ALDH1A1 969/4885MAPT 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.